Elicio Therapeutics has granted inducement stock options to a newly hired employee as part of its compensation package. The grant, issued on February 17, 2026, consists of 30,300 options with an exercise price of $8.59 per share, according to company filings.
The options follow a standard four-year vesting schedule, with 25% of the grant vesting on the first anniversary of the award date. The remaining 75% will vest in equal monthly installments over the subsequent three years, contingent upon the employee's continued employment with the company. Such inducement grants are commonly used by companies to attract qualified talent for key positions.
Inducement awards represent a strategic hiring practice in competitive talent markets, allowing companies to offer equity-based compensation to prospective employees who may forgo unvested benefits from previous employers.